Form 4: Ultragenyx Legal Officer Sells Shares for Tax

Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 8,135 shares of common stock to cover tax withholdings following the conversion of performance stock units.

Summary

• Karah Herdman Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc. [RARE], reported transactions involving company common stock.
• On March 1, 2026, Parschauer acquired 11,137 shares of common stock from previously granted performance stock units (PSUs) upon certification of performance metrics.
• On March 2, 2026, Parschauer sold 8,135 shares of common stock at a weighted average price of $22.80 per share to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
• Following these transactions, Parschauer beneficially owns 76,346 shares of Ultragenyx common stock.
• The sale was conducted under a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The acquisition of shares from PSUs suggests performance targets were met, while the subsequent sale for tax purposes is a routine, pre-planned event that doesn't necessarily signal a negative outlook.

Positives

• The acquisition of 11,137 shares from performance stock units indicates that performance metrics were met, suggesting positive company performance or individual achievement.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a discretionary one based on new information.

Negatives

• A sale of 8,135 shares by an executive, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

na

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to executive compensation and tax obligations, are common in the biotechnology and pharmaceutical sectors. While a sale reduces an executive's direct stake, sales for tax purposes following vesting events are generally not interpreted as a lack of confidence in the company's future, especially when conducted under a Rule 10b5-1 plan.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of executives selling shares to cover tax liabilities upon the vesting of equity awards is a standard compensation practice across industries, including biotechnology. This is comparable to similar transactions seen at peer companies like BioMarin Pharmaceutical Inc. (BMRN) or Sarepta Therapeutics, Inc. (SRPT), where executives frequently execute pre-planned sales to manage tax obligations arising from equity compensation.

Stakeholder Impact

• Shareholders: The executive's beneficial ownership decreased slightly, but the transaction is routine and unlikely to signal a change in company fundamentals.
• Employees: The vesting of PSUs and RSUs indicates the company's compensation structure is functioning as intended.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive acquired shares through performance-based awards and subsequently sold a portion to cover tax obligations under a pre-arranged plan. This type of transaction is common and generally does not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions, rather than this specific insider filing.

Keywords

Ultragenyx Pharmaceutical, RARE, Form 4, Insider Trading, Stock Sale, Performance Stock Units, Restricted Stock Units, Executive Compensation, Karah Herdman Parschauer, Biotechnology, Pharmaceuticals